Immune checkpoint receptors, including PD-1 and CTLA4, are expressed on the surface of immune cells, whereas the cognate ligands (PD-L1/PD-L2 and CD86/CD80) are expressed on the tumor cell surface. This evidence concerns the gene CTLA4 and neoplasm.